The thromboxane receptor antagonist BAY u3405 reverses prostaglandin D2 (PGD2)-induced bronchoconstriction in the anaesthetised guinea pig.
Francis
H P
HP
Bayer UK, Ltd., Research Department, Slough, England.
Morris
T G
TG
Thompson
A M
AM
Patel
U P
UP
Gardiner
P J
PJ
D000818:Animals; D016084:Bronchoconstriction / Q000187:drug effects*; D002227:Carbazoles / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D006168:Guinea Pigs; D007213:Indomethacin / Q000494:pharmacology; D008176:Lung Volume Measurements; D008297:Male; D015230:Prostaglandin D2 / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D011982:Receptors, Prostaglandin / Q000037:antagonists & inhibitors*; D017482:Receptors, Thromboxane; D013015:Sotalol / Q000494:pharmacology; D013449:Sulfonamides / Q000494:pharmacology*; D013931:Thromboxanes / Q000037:antagonists & inhibitors*
D002227:Carbazoles; D011982:Receptors, Prostaglandin; D017482:Receptors, Thromboxane; D013449:Sulfonamides; D013931:Thromboxanes; D013015:Sotalol; C063119:ramatroban; D015230:Prostaglandin D2; D007213:Indomethacin